Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition, we show that YAP<sup>S127A</sup>-transduction of the human MDA-MB-231 breast cancer cell line (that carry a similar KRAS mutation) enhances their metastatic activity in vivo.
|
31772328 |
2020 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Treatment of breast cancer cells with chlorhexidine decreases KRAS protein levels, while a KRAS gene transiently expressed by a promoter lacking a G4 is not affected.
|
29481610 |
2018 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
|
28843257 |
2017 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.
|
28454346 |
2017 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the correlation among poorly differentiated carcinoma, epithelial to mesenchymal transition (EMT) phenomenon, and expression of NF-kB, Sonic Hedgehog (SHH), K-RAS, and PTX3 in breast cancer in 100 breast biopsies.
|
26563370 |
2016 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We report that mutations in both PIK3CA and KRAS are required for the greatest aspirin sensitivity in breast cancer, and that the GSK3β protein was hyperphosphorylated in aspirin-treated double knockin cells, but not in other clones/treatments.
|
26915040 |
2016 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
|
25940428 |
2016 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we conducted sequence analysis of PIK3CA, BRAF, and KRAS and determined relationships with the occurrence of breast cancer in women from Qinghai.
|
26600545 |
2015 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Finally, hormone replacement therapy (HRT) discontinuation in KRAS-variant patients was associated with a diagnosis of triple negative BC (P < 0.001).
|
25961464 |
2015 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, silencing of SAF-1 expression in breast cancer cells by SAF-1-specific short hairpin RNAs (shRNAs) significantly reduced H-Ras and K-Ras mRNA level.
|
25449683 |
2015 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The present study was conducted to test the hypothesis that K-RAS activation is involved in breast cancer risk of south Indian population.
|
25921169 |
2015 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements.
|
25257380 |
2015 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The genes of MTUS1, CD44, CCNB1, CCND2 and KRAS with specific SNP loci may be used as biomarkers for diagnosis of breast cancer.
|
25408372 |
2015 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, this study demonstrates that KRAS is a critical regulator for the metastatic behavior associated with mesenchymal features of breast cancer cells, implicating a novel therapeutic target for basal-type breast cancer.
|
25633745 |
2015 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings provide clues regarding the role of miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS translation both in vitro and in vivo. miR-200c could be a potential therapeutic target in breast cancer.
|
26392416 |
2015 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We observed no statistically significant association between BC risk and the let-7a KRAS rs712 polymorphism (GT vs GG, OR = 0.98, 95%CI = 0.66-1.46; TT vs GG, OR = 0.78, 95%CI = 0.28-2.21).
|
26681038 |
2015 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
AKT1, KRAS and PIK3CA mutations and PTEN loss all exist in women with breast cancer in the mainland China.
|
25816324 |
2015 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We show that KRAS is a predicted target of miR-200c and that the protein expression of KRAS inversely correlates with the miR-200c expression in a panel of human breast cancer cell lines.
|
24368337 |
2014 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Androgen-induced AR activating signal upregulates let-7a that targets CMYC and KRAS and contributes to ER-, PR-, AR+ breast cancer pathogenesis.
|
24172884 |
2014 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The incorporation of molecular profiling into routine clinical practice has already been adopted in some tumor types, such as human epidermal growth factor receptor 2 (HER2) testing in breast cancer and KRAS genotyping in colorectal cancer, providing a guide to treatment selection that is not afforded by histopathologic diagnosis alone.
|
23589555 |
2013 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate whether the hormone receptor expression, HER2 and MYC genes and their protein status, and KRAS codon 12 mutations may be prognostic or predictive biomarkers of breast cancer.
|
23555992 |
2013 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Biomarkers such as HER2 for breast cancer or EGFR mutation for lung cancer and KRAS mutation in colon cancer have contributed to identify a patient population that might show a good and bad treatment response, respectively.
|
21652149 |
2012 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Investigating the impact of Ido1 gene disruption in mouse models of oncogenic KRAS-induced lung carcinoma and breast carcinoma-derived pulmonary metastasis, we have found that IDO deficiency resulted in reduced lung tumor burden and improved survival in both models.
|
22822050 |
2012 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Associations between the KRAS genotype and breast cancer or breast tumor characteristics were assessed using chi-square test and logistic regression models.
|
22436609 |
2012 |